Revolutionizing IBD therapy: Insights into contemporary treatment strategies

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This review evaluates existing treatments for inflammatory bowel disease, highlighting limitations and the need for novel approaches.

Approximately 10% to 30% of inflammatory bowel disease patients do not respond to conventional treatments, indicating a significant treatment gap.
Current therapies like biologics and corticosteroids have limitations, including side effects and potential long-term safety concerns.
Research into peptide-based therapies presents a promising direction for improving inflammation modulation and mucosal healing in IBD management.
The rising prevalence of inflammatory bowel disease highlights the urgent need for innovative treatment strategies to address existing challenges.

Kushwaha et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

This review evaluates existing treatments for inflammatory bowel disease, highlighting limitations and the need for novel approaches.

Approximately 10% to 30% of inflammatory bowel disease patients do not respond to conventional treatments, indicating a significant treatment gap.
Current therapies like biologics and corticosteroids have limitations, including side effects and potential long-term safety concerns.
Research into peptide-based therapies presents a promising direction for improving inflammation modulation and mucosal healing in IBD management.
The rising prevalence of inflammatory bowel disease highlights the urgent need for innovative treatment strategies to address existing challenges.

Kushwaha et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark